Special Issue

Sequence Variants in Breast/Ovarian Cancer Susceptibility Genes: From Risk Assessment to Clinical Management in Carrier Individuals and Their Blood Relatives

Message from the Guest Editors

This Special Issue aims to advance our knowledge of both basic and clinically relevant aspects pertaining to the assessment and management of the cancer risk associated with sequence variants in breast/ovarian cancer susceptibility genes. We welcome original articles and reviews covering a broad spectrum of research topics, including the following:

- High- and moderate-risk gene variants and the clinical management of carrier individuals and their noncarrier blood relatives;
- Other cancer phenotypes associated with (likely) pathogenic variants in breast/ovarian cancer susceptibility genes;
- Uses of PRS for risk refinement (real-world studies on models integrating multiple risk factors are encouraged);
- Evidence supporting variant classification, e.g., segregation analyses, functional studies, or the characterization of splice-site variants (multifactorial analyses are especially welcome);
- Molecular mechanisms of response/resistance to platinum and PARP inhibitors;
- Preventive and therapeutic (surgical and medical) options for carrier individuals.

Guest Editors

Dr. Arcangela De Nicolo

Institute of Oncology and Molecular Genetics, Riga Stradins University, Riga, Latvia

Dr. Miguel De la Hoya

Molecular Oncology Laboratory, IdISSC (San Carlos Biomedical Research Institute), Madrid, Spain



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/205677

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers



31 December 2025



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

